Rituximab use and survival after diffuse large B-cell or follicular lymphoma: A population-based study

Leukemia and Lymphoma

Volumn 54, Issue 4, 2013, Pages 743-751

  Keegan, Theresa H M ^a,b   Moy, Lisa M ^a   Foran, James M ^c   Alizadeh, Ash A ^b   Chang, Ellen T ^a,b   Shema, Sarah J ^a   Schupp, Clayton W ^a   Clarke, Christina A ^a,b   Glaser, Sally L ^a,b  

^a CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Diffuse large B cell lymphoma; Disparities; Follicular lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG USE; ETHNICITY; FEMALE; FOLLICULAR LYMPHOMA; HEALTH INSURANCE; HUMAN; INCOME; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEGRO; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; ODDS RATIO; SEER PROGRAM; TREATMENT OUTCOME;

EID: 84879538665     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.727415     Document Type: Article

References (50)

1. Yu XQ, Chen WH, O' Connell DL. Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer 2010; 10: 231.
2. Keegan TH, McClure LA, Foran JM, et al. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: A population-based study. J Clin Oncol 2009; 27: 3044-3051.
3. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008; 168: 469-476.
4. Foran JM, McClure LA, Clarke CA, et al. Impact of socioeconomic status and race/ethnicity on survival in Diffuse large B-cell lymphoma (DLBCL): A population-based study. Blood 2009; 114(Suppl. 1): Abstract 1954.
5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Non-Hodgkin's lymphoma (version 1.2005) [Internet]. Available from: www.nccn.org/professionals/physician-gls/PDF/nhl.pdf
6. National Cancer Institute. Adult non-Hodgkin's lymphoma (PDQ): Treatment (health professional version) [Internet]. Available from: Http://www.cancer.gov/ cancerinfo/pdq/treatment/adult-nonhodgkins/healthprofessional
7. Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive Diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 121: 44-48.
8. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447-8452.
9. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
10. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifi cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
11. Sacchi S, Pozzi S, Marcheselli L, et al. Introduction of rituximab in front-line and salvage therapies has improved outcome of advancedstage follicular lymphoma patients. Cancer 2007; 109: 2077-2082.
12. van Oers M H. R ituximab maintenance therapy: A step forward in follicular lymphoma. Haematologica 2007; 92: 826-833.
13. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with Diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l' Adulte. J Clin Oncol 2005; 23: 4117-4126.
14. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with Diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
15. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis Diffuse large-B-cell lymphoma: A randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
16. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma signifi cantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-4423.
17. Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim followup of a multicenter phase II trial. Semin Oncol 2002; 29: 25-29.
18. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-3301.
19. Demark-Wahnefried W, Hars V, Conaway MR, et al. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr 1997; 65: 1495-1501.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
21. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Kocs D, Fendrick AM. Effect of off -label use of oncology drugs on pharmaceutical costs: The rituximab experience. Am J Manag Care 2003; 9: 393-400; quiz 401-392.
23. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with Diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
24. Zelenetz AD. Non-Hodgkin's lymphoma clinical practice guidelines. J Natl Compr Canc Netw 2004; 2: 286-336.
25. Pazdur R. 2011 FDA approval for rituximab. In: Cancer drug information. National Cancer Institute. Available from: Http://www. cancer.gov/cancertopics/ druginfo/fda-rituximab
26. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: First report of the national LymphoCare study. J Clin Oncol 2009; 27: 1202-1208.
27. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modifi ed CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defi ned using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248-2260.
28. Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: Diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011; 52: 994-1002.
29. Griffi ths R, Gleeson M, Knopf K, et al. Racial differences in treatment and survival in older patients with Diffuse large B-cell lymphoma (DLBCL). BMC Cancer 2010; 10: 625.
30. Shih YC, Elting LS, Halpern MT. Factors associated with immunotherapy use among newly diagnosed cancer patients. Med Care 2009; 47: 948-958.
31. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
32. Persky D O, Unger J M, Spier C M, et al. Phase II study of rituximab plus three cycles of CHOP and involved-fi eld radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008; 26: 2258-2263.
33. Cronin DP, Harlan LC, Clegg LX, et al. Patterns of care in a population-based random sample of patients diagnosed with non-Hodgkin's lymphoma. Hematol Oncol 2005; 23: 73-81.
34. Schoenborn CA. Marital status and health: United States, 1999-2002. Adv Data 2004: 1-32.
35. Manzoli L, Villari P, Pironi G M, et al. Marital status and mortality in the elderly: A systematic review and meta-analysis. Soc Sci Med 2007; 64: 77-94.
36. Johnson NJ, Backlund E, Sorlie PD, et al. Marital status and mortality: The national longitudinal mortality study. Ann Epidemiol 2000; 10: 224-238.
37. Nabhan C, Byrtek M, Taylor M D, et al. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: Report from the National LymphoCare Study. Cancer 2012; 2012: 27513.
38. Keating GM. Rituximab: A review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and Diffuse large B-cell lymphoma. Drugs 2010; 70: 1445-1476.
39. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8: 288-334.
40. Dotan E, Aggarwal C, Smith MR, et al. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T 2010; 35: 148-157.
41. Roswall N, Olsen A, Christensen J, et al. Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003. Eur J Cancer 2008; 44: 2058-2073.
42. Wang M, Burau KD, Fang S, et al. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large populationbased cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008; 113: 3231-3241.
43. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006; 24: 1582-1589.
44. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of Diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
45. Krol AD, le Cessie S, Snijder S, et al. Non-Hodgkin's lymphoma in the Netherlands: Results from a population-based registry. Leuk Lymphoma 2003; 44: 451-458.
46. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108: 1504-1508.
47. Diamond C, Taylor T H, Anton-Culver H. C haracteristics and survival of patients with non-Hodgkin's lymphoma with and without acquired immunodefi ciency syndrome. Hematol Oncol 2002; 20: 177-187.
48. Clarke C, O' Malley CD. Non-Hodgkin lymphoma. In: Ries LAG, Young JL, Keel GE, et al., editors. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda: National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007. pp. 237-242.
49. Spina M, Gloghini A, Tirelli U, et al. Th erapeutic options for HIVassociated lymphomas. Expert Opin Pharmacother 2010; 11: 2471-2481.
50. Ribera JM, Oriol A, Morgades M, et al. Safety and Efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodefi ciency virus-associated Diffuse large B-cell lymphoma: Results of a phase II trial. Br J Haematol 2008; 140: 411-419.